A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects.
Subjects with moderate to severe Exocrine Pancreatic Insufficiency due to pancreatic cancer.
Histologically proven metastatic adrenocortical carcinoma (ACC) evaluable by CT imaging with the majority of disease confined to the peritoneal cavity and surgically resectable to a residual size of less than 1 cm in patients who are >18 years of age.
Phase 2 trial to determine efficacy of this therapeutic strategy in ACC. Patients will undergo cytoreductive surgery and heated intraperitoneal chemotherapy.
The purpose of this study is to compare the efficacy and safety of PEGPH20 combined with nab-paclitaxel & gemcitabine in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma.
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma